← Leaderboards
Masaaki Tamura
Vanderbilt University
$481,629
Attributed
$766,805
Total exposure
5
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $380K · FY2009–17$500K$375K$250K$125K$0
'09
'10
'11
'12
'13
'14
'15
'16
'17
Funding mix
By agency
NIH$766,805 · 5
By mechanism
R15$380,000 · 1
U43$190,353 · 1
R03$151,313 · 1
P20$45,139 · 1
P30$0 · 1
Top collaborators
- Jeffrey Robert Comer1 shared
- Taneli Jouhikainen1 shared
Most similar at Vanderbilt University
Same institution · by research overlap
- Brian O Bachmann$7,858,203
- Richard M Caprioli$30,630,395
- Jason Becker$6,034,764
- Jeffrey M. Davidson$7,827,553
- Rachael Wolters$368,550
Others in their field
Top investigators on “Analytical Chemistry”
- Harold G Craighead · Cornell University$39,497,888
- Clark Algaier · Midwest Research Institute$33,924,337
- Reshan Fernando · Research Triangle Institute$28,999,659
- Bala Raja · Luminostics, Inc.$28,624,460
- Robert J Hamers · University Of Wisconsin-Madison$21,159,624
- Kristin Aillon · Midwest Research Institute$20,814,315
Research focus
Analytical ChemistryBiomedical Equipment ResourceAminoacidComputer Assisted Sequence AnalysisNeoplasm /CancerOncologyProtein SequenceBiomedical FacilityGene TargetingAngiotensin IiEnzyme Induction /RepressionAdverse EffectsAthymic MouseEffective TherapyAngiotensin ReceptorCytochrome P450Cancer CellChemical CarcinogenChemical CarcinogenesisBaseCaptoprilAdenocarcinomaAttenuatedCancer Prevention
Grant awards (13)
Cancer-targeted local pulmonary immunotherapy with PD-L1 inhibitory peptide secretory genes for the treatment of lung cancer$380,000
R15 · FY2017 · CA · contact PI
Targeted nanoparticle gene therapy for lung cancer$190,353
U43 · FY2013 · CA
NANOPARTICLE-BASED DUAL GENE THERAPY FOR LUNG ADENOCARCINOMA$45,139
P20 · FY2009 · RR · contact PI
Prevention of colon cancer by an AT2 receptor antagonist$75,563
R03 · FY2002 · CA
Core--Peptide sequencing and amino acid analysis$0
P30 · FY2002 · CA
Core--Peptide sequencing and amino acid analysis$0
P30 · FY2002 · CA
Prevention of colon cancer by an AT2 receptor antagonist$75,750
R03 · FY2001 · CA
Core--Peptide sequencing and amino acid analysis$0
P30 · FY2001 · CA
Core--Peptide sequencing and amino acid analysis$0
P30 · FY2001 · CA
Core--Peptide sequencing and amino acid analysis$0
P30 · FY2000 · CA
Core--Peptide sequencing and amino acid analysis$0
P30 · FY2000 · CA
Core--Peptide sequencing and amino acid analysis$0
P30 · FY2000 · CA
Core--Peptide sequencing and amino acid analysis$0
P30 · FY2000 · CA